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BACKGROUND: In vivo stains are the prompt resources, which have emerged in recent years to aid as 
clinical diagnostic tools in detecting early potentially malignant and malignant lesions. Toluidine blue, 
by its property of retaining in the increased DNA and RNA cellular activity areas, aids in delineating the 
suspicious areas. However, it is hazardous if swallowed, and has been shown to have toxicity to 
fibroblasts. Methylene blue has a similar chemical structure and exhibits similar physicochemical 
properties as toluidine blue. It is less toxic to the human body and has recently been proposed for 
screening some gastrointestinal or prostate tumors. The application of this material in detecting oral 
lesions has so far not been addressed. The objective of this study was to evaluate the sensitivity and 
reliability of in vivo staining with methylene blue as a diagnostic adjunct in screening for oral malignant 
or potentially malignant lesions. 
METHODS: The present study involved the examination of 75 patients suspected of having oral 
malignant or potentially malignant lesions by methylene blue staining. The results of methylene blue 
uptake were compared with a simultaneous biopsy of these lesions.  
RESULTS: The overall sensitivity was 95% (100% for malignancy and 92% for potentially malignant 
lesions) and specificity was 70%. The positive predictive value was 91% and negative predictive value of 
80% was observed in the study. 
CONCLUSION: We consider that methylene blue staining is a useful diagnostic adjunct in a large, 
community-based oral cancer screening program for high-risk individuals.  




   
Oral cancer is one of the most frequently observed 
malignancies in the world and shows marked 
geographic differences in occurrence. Oral cancer 
is common where betel quid chewing, bidi 
smoking, alcohol and tobacco consumption are 
high. Thus, it is frequently observed in South East 
Asia where more than 100,000 new cases are 
reported every year (1). 
There are about 700,000 new cases of cancers 
every year in India out of which tobacco related 
cancers are about 300,000. The cost of treatment 
of oral cancer is about 3.5 lakh. This can be 
completely prevented by simple changes in 
lifestyle and regular screening. About 2000 deaths 
a day in India is tobacco related (2). 
Early detection of oral carcinoma is of 
paramount importance as it can best be cured at its 
earliest stage. Several studies have shown that 
patient mortality reduces considerably when oral 
carcinoma is treated at initial stage (3). Similarly, 
it is equally important to detect and treat 
potentially malignant lesions as their progress to 
malignancy can be prevented (4). 
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Among the diagnostic tools, in vivo staining  is 
advocated as a simple, inexpensive, and fairly 
sensitive method (4). Periodic clinical examination  
 
 





by doing vital staining reduces the mortality rate 
by 32% in high risk individuals (4). Adjunctive 
aids such as Toluidine blue (tolonium chloride) 
have been widely accepted in large scale screening 
for oral cancer diagnosis (5-10). The 
disadvantages of Toluidine blue are its hazardous 
effect if swallowed and its reported toxicity to 
fibroblasts (4). 
Methylene blue has a similar chemical 
structure and exhibits similar physicochemical 
properties to Toluidine blue. It is less toxic to the 
human body and recently been proposed for 
screening some gastrointestinal, prostate and 
bladder tumors (11-13). The application of this 
material in detecting oral lesions has not been 
extensively addressed. Hence, this study was 
undertaken to highlight the efficacy of Methylene 
Blue staining in the early detection of potentially 
malignant and malignant lesions of the oral 
mucosa. 
 
MATERIALS AND METHODS 
 
Subjects: The efficacy of 1% methylene blue in 
the detection of potentially malignant and 
malignant oral lesions/condition was evaluated 
among a group of 125 patients at risk for oral 
malignancy. The subjects were divided into two 
groups: 
Cases: Seventy-five patients with clinical 
suspicions of oral potentially malignant and 
malignant lesions were selected at random from 
the Department of Oral Medicine and Radiology 
for the study group. The patients did not have 
previous history of oral cancer and had not 
undergone any previous treatment for oral 
malignancy. 
Controls: Ffty controls without the habits of 
tobacco in any form (smoking and quid chewing) 
were included in our control study.  
The clinical data regarding the patients’ 
gender, age and habits of tobacco use were 
collected. All the patients were subjected to a 
systematic oral examination for clinical diagnosis 
which was categorized clinically into the 
following 4 groups: 
Group 1: Homogeneous leukoplakia, i.e. white, 
uniform, flat lesion with a smooth,  wrinkled, or 
corrugated surface, not able to be scraped 
Group 2: Nonhomogeneous leukoplakia-white 
lesion with irregular and exophytic surface 
Group 3: Erythroplakia-red lesion with ill-defined 
margin 
Group 4: Carcinoma-localized and superficial 
ulcero-proliferative lesions. 
Subjects in the study as well as in control 
groups were subjected to methylene blue staining 
procedure. 
 
Formulation of tissue stain: Methylene blue dye 
system had two solution bottles. The dye rinse 
solution (Bottle A) had 1% methylene blue, 1% 
malachite, 0.5% eosin, glycerol and 
dimethylsulfoxide. Pre- and post-rinse solution 
(Bottle B) had 1% lactic acid and purified water. 
 
Staining protocol: The oral cavity was examined 
and location, size, morphology and surface 
characteristics of suspect lesions were recorded 
and photographed. All patients rinsed their mouths 
with 1% lactic acid (Bottle B) for 20 seconds to 
remove food debris and excess saliva and to 
provide a consistent oral environment. The 
mucosa of the target area was gently dried with 
gauze to ensure that the lesion was not 
contaminated with saliva. For equivocal staining, 
1% methylene blue dye (Bottle A) was applied 
directly over the suspected area with the help of 
cotton and kept in place for 20 seconds.  
Patients then rinsed their mouths again with 
1% lactic acid (Bottle B) for 20 seconds to wash 
out the excess dye. The pattern of dye retention 
was assessed by the intensity of stain retention on 
the lesion: 
 Local, stippled, patchy and deep blue stains  
 Wide, shallow or faint blue stains  
For equivocal staining, 1% lactic acid (Bottle 
B) solution was applied with cotton rolls to wipe 
out the staining surface. If the blue stain was 
washed out, negative reaction was recorded and 
vice versa. If the patient had a highly suspicious 
lesion that was not stained by the solution, he/she 
was instructed to revisit within 14 days to repeat 
the test in order to reduce the false-negative rate.  
Interpretation of stain: The staining pattern 
observed was divided into 3 categories: 
Dark uptake: Cases where the lesion or portion of 
the lesion stains dark blue in a solid or stippled 
fashion 
Light uptake: Well circumscribed light blue 
staining pattern with intensity of stain lower than 
lesions showing dark uptake 




No uptake/ Equivocal staining: Cases where 
there are areas of mucosa which stains with a faint 
blue color 
The results of methylene blue dye staining were 
recorded with photographs.  Incisional/excisional 
biopsy was performed simultaneously in the 
suspected lesions to compare the accuracy of the 
diagnostic capability of methylene blue. 
Histologic examination: For the subjects in the 
study group which consisted of 75 patients, a 
punch of biopsy was performed in the most 
obvious staining area of the suspicious lesion of 
patients under local anaesthesia. If there was no 
dye uptake in the lesions, the biopsy specimen was 
taken from the area judged by a specialist’s 
experience. The specimens were then fixed in 10% 
formalin and processed in the pathology 
laboratory for initial routine pathologic diagnosis. 
Thus, the false positives, the false negatives, the 
sensitivity and the specificity were calculated. 
Biopsy was not performed on subjects in the 
control group without dye uptake considering 
ethical issues.     
The dye uptake results were correlated with 
the histopathological report in order to estimate 
the false positives, false negatives, the sensitivity 
and the specificity rates. All the specimens were 
microscopically evaluated by pathologists who 
were blind to the results of methylene blue stain. 
The pathology reports of the lesions were 
classified as:  
(1) Dysplastic lesions which were further 
subcategorized as mild, moderate and severe 
dysplasia 
(2) Non-dysplastic lesions including epithelial 
hyperplasia, lichen planus and hyperkeratosis 
(3) Malignant lesions including verrucous 
carcinoma and oral squamous cell carcinoma. 
Statistical analysis: Statistical analysis was 
performed, including sensitivity, specificity, 
positive and negative predictive values. The 
association of methylene blue uptake and 
pathologic diagnosis was analyzed using Yates 
corrected chi-square test. A p value (probability 





Subject characteristics: One hundred and 
twenty- five subjects (75 patients and 50 volunteer 
students) were enrolled in this study. The patients’ 
age (patient group) ranged from 21 to 73 years 
(mean age 51.3 years), with the male to female 
ratio being 14:1. The student’s ages (control 
group) ranged from 19 to 25 years (mean age 22 
years).  
The oral mucosal lesions selected in this 
study were divided clinically into four categories – 
homogenous leukoplakia in 39 patients, non-
homogenous leukoplakia in 27 patients, oral 
carcinoma in 4 and erythroplakia in 5. The results 
of the present study showed three types of staining 
patterns with respect to the clinical diagnosis of 
oral mucosal lesions (Table 1). 
  Table 1: Methylene blue dye uptake 
 
Uptake Pattern HL* NHL
 
Carcinoma Erythroplakia Number of Lesions 
Dark uptake 0 39 5 4 48 
Light uptake 12 0 0 0 12 
No uptake/equivocal staining 15 0 0 0 15 
Total 27 39 5 4 75 
*HL – Homogenous Leukoplakia   NHL- Non Homogenous Leukoplakia 
 
Methylene blue staining related to the grade of 
pathology: The histopathological diagnosis of oral 
lesions and the results of staining are shown in 
Table 2. The pathologic grade was classified as 
absence of dysplasia (mild, moderate and severe 
dysplasia) and OSCC as previously described in 
the methods section. The cases which showed dark 
blue uptake of the methylene blue dye were 
diagnosed histologically as mild dysplasia in 5 
patients and moderate to severe dysplasia and oral 
squamous cell carcinoma in 41 patients (Figure 1). 
The cases which showed light uptake clinically 
were diagnosed histopathologically as non-
dysplastic on 5 instances and mild dysplasia in 12 





cases (Figure 2). There were 12 cases which 
showed equivocal uptake and were histologically 
proven as non-dysplastic oral mucosal lesions 
(Figure 3). 
 




Light Uptake No uptake or Equivocal 
Stain 
TOTAL 
No dysplasia 0 5 12 17 
Mild dysplasia 5 12 0 17 
Moderate /severe dysplasia/ OSCC 41 0 0 41 




1a: Clinical photograph showing non-
homogenous leukoplakia on right buccal mucosa 
1b: Clinical photograph showing dark uptake of 
stain after application of methylene blue dye  





2a: Clinical photograph showing homogenous 
leukoplakia on right buccal mucosa 
2b: Clinical photograph showing light uptake of 
stain after application of methylene blue dye  




3a: Clinical photograph showing homogenous 
leukoplakia on right buccal mucosa 
3b: Clinical photograph showing very mild uptake 
of stain or equivocal staining after application of 
methylene blue dye  
3c: Photomicrograh showing no dysplastic 
features (X100) 
 
In this study, 55 of 58 pathologically proven oral 
malignant or potentially malignant lesions were 
positive with deep and focal methylene blue 
staining. The overall sensitivity was 95%. The 
three false negative cases were homogeneous 
leukoplakia on the buccal mucosa with 
histopathological diagnosis showing no dysplastic 
features. These lesions were stained with a faint 
blue colour.  
In the study, 12 of 15 benign lesions showed 
negative staining. Thus, the specificity was 70%. 
The results of staining with methylene blue for all 
lesions correlated well with the pathologic 
diagnosis as summarized in Table 3. Yates 
corrected chi-square showed significant 




differences among cancer/precancerous lesions, 
benign lesions and normal control groups (p < 
0.01). Overall, the positive predictive value was 
91% (55/60), and the false predictive value was 
80% (12/15). 
 
Table 3. Efficacy of methylene blue application in pathologically proved cancer/precancerous lesion 
 
Histological Diagnosis  Positive (%) Negative (%)     P Value 







P= 0.0000 (p<0.001) 
P=0.0010 (P<0.01) No Dysplasia (n=17) 





Oral cancer is very common in Southeast Asia, 
including India. Areca nut chewing, tobacco and 
alcohol consumption are the main etiologic factors 
inducing carcinogenesis in oral mucosa. 
Individuals with all the habits of smoking, alcohol 
consumption and areca nut chewing were reported 
to have 123 times the risk of people without such 
habits (14). Thus, oral cancer screening of high-
risk individuals is very important in these 
countries.  
For a large-scale community screening, 
certain dye materials help to identify abnormal 
mucosa tissue and raises oral examiners attention. 
The patients with suspicious lesions may be 
referred to oral physicians for further 
examinations. 
The concept of two-step process of cancer 
development in the oral mucosa, i.e., the initial 
presence of a precursor (pre-cancerous) lesion 
subsequently developing into cancer is well 
established and the early detection of oral mucosal 
epithelial dysplasias could potentially halt the 
progression of these lesions into malignant 
transformation (15,16). Thus, establishment of 
useful and objective techniques adjunctive to 
clinical judgments and microscopic diagnosis has 
contributed to the control of oral cancers (17).
 
In vivo staining reveals cytological details 
that might otherwise not be apparent. However, 
staining can also reveal where certain chemicals or 
specific chemical reactions are taking place within 
cells or tissues and thus aid in accelerating 
biopsies, diagnosis and treatment (18). The vital 
staining methods were used at first in medicine for 
detecting cervical dysplasia and carcinoma in situ 
in the 1960s (19). Niebel and Chomet were the 
pioneers who used dye material to detect oral 
cancer in 1964 (20). Toluidine blue dye is known 
as one of the diagnostic adjuncts to detect oral 
cancer/precancerous lesions. The efficacy of this 
technique has been evaluated in many reports with 
diverse results. It has yielded sensitivities between 
72% and 100%, and specificities between 45% 
and 67%, in detecting suspicious malignancies (5-
10). However, the Material Data Safety Sheet 
indicates that toluidine blue is probably toxic by 
ingestion, and it is seldom used for detecting 
cancers in other parts of the human body (21).
 
Methylene blue is another recently proposed dye 
for in vivo staining used in endoscopic 
examination.
 
Its application has been reported 
recently in detecting some gastrointestinal 
abnormalities such as Barrett’s esophagus (22-24) 
gastric cancer (25) prostate cancers (11,12) and 
also bladder cancer (26). The exact mechanism for 
the uptake of methylene blue dye in epithelial cells 
is still not very clear. However, it resembles 
toluidine blue dye in its acidophilic characteristics. 
Methylene blue may penetrate into cells with an 
abnormal increase in nucleic acid, thus resulting in 
different uptake between normal and highly 
dysplastic/malignant cells. Usage of the methylene 
blue technique in detecting oral malignant or 
potentially malignant lesions has been reported 
only twice thus far (4,27). This study therefore 
aimed to study the staining pattern/dye uptake 
pattern of methylene blue in oral potentially 
malignant and malignant lesions. 
In this study, the usefulness, reliability and 
shortcomings of methylene blue dye uptake in 
tissues that have undergone malignant or 
dysplastic changes have been studied. Possible 
advantages of methylene blue staining in high risk 
population have also been detected. The study was 





conducted on high risk patients with unconfirmed 
mucosal lesions, in a prospective trial to test its 
diagnostic accuracy in the early detection of 
potentially malignant and malignant lesions, the 
staining pattern of the dye and with emphasis on 
sensitivity, specificity and the significant levels. 
In the study the lesions showing dark uptake 
consisted of 39 cases of non-homogenous 
leukoplakia, 5 cases of OSCC and 4 cases of 
erythroplakia. All the cases which showed light 
uptake were homogenous leukoplakia. A 
significant difference was observed in the staining 
pattern and intensities in methylene blue dye 
uptake in homogenous and non-homogenous 
leukoplakia due to the difference in the activity of 
cells in both stages of the disease. 
Out of the 25 cases of homogenous 
leukoplakia which were diagnosed clinically, only 
12 cases stained positively for methylene blue dye, 
and 15 cases were negative for methylene blue 
stain. Of these, 15 cases which did not stain 
positively for methylene blue dye, 12 did not show 
any dysplastic features on histopathology. These 
12 cases were true negatives. Three of the 15 cases 
which showed negative staining showed dysplastic 
features on histopathology. These were the false 
negatives. The false negative uptake of this study 
may be related to areas of interspersed keratin or 
normal mucosa that did not pick up the stain as 
keratin does not allow stain penetration. Necrotic 
portions and deeper extension into tissue planes, 
of extensive or asymptomatic carcinomas may 
also not stain for the same reason as mentioned 
above. As for false-negatives, we consider that the 
ambiguous light blue stains may be misinterpreted 
as negative but clinically suspicious of malignancy 
still need further biopsy to prove the diagnosis 
pathologically.  
In this study, it was also seen that of the 39 
cases diagnosed clinically as non-homogenous 
leukoplakia, all the 39 cases stained positively for 
methylene blue dye and 34 of the 39 cases showed 
dysplastic features or were OSCC on 
histopathological examination. Five cases which 
stained positively for methylene blue stain 
clinically but did not show any features of 
dysplasia pathologically were the 5 false positives 
of this study. These false positives may be because 
although, normal tissues should not absorb stain. 
However, small areas of intense stain may be 
mechanically retained. Larger areas of excess stain 
may accumulate on the dorsum of the tongue 
coated with surface debris and gingival crevices. 
Occasionally, a light blue film may be observed 
over a large area of the mucosa as a result of 
saliva tinged with the dye. The high false positive 
rate may also be related to the retention of stain in 
inflamed and trauma areas (8). Other causative 
factors may include the irregular, papillary or 
digital surfaces of the lesions, which may cause 
the mechanical retention of dye, contamination of 
saliva and plaque, retention of dye material in 
papilla of the tongue or minor salivary gland ducts 
over the mucosa. Verrucous hyperplasia and 
carcinoma may also show mechanical retention of 
the dye. 
Among all the statistical values, sensitivity 
rate and false negatives were the most important in 
evaluating the efficacy of certain diagnostic tools 
for detecting abnormal lesions. Sensitivity 
represents the proportion of histologically proved 
malignant/potentially malignant lesions which are 
detected by positive methylene blue staining. In 
this study, 55 of the 58 pathologically proved 
malignant/potentially malignant lesions were 
positive with deep and focal methylene blue 
staining. The overall sensitivity of 95% (100% for 
malignancy and 92% for potentially malignant 
lesions) was reported, compared to the 72–100% 
sensitivity reported in previous studies (5–10). 
The sensitivity values of this study indicate that 
using methylene blue dye in the detection of 
potentially malignant and malignant lesions is 
acceptable. In the aspect of specificity, we 
obtained a value 70% (12/15) with a resulting 
false positive rate of 30%. These results are in 
accordance to previous study which reported 
specificity rate of 69% (21). The lower specificity 
rate of the present study indicates that not all the 
lesions which show dye uptake clinically were 
found to be dysplastic or malignant lesion 
pathologically. Therefore, biopsy remains the gold 
standard for diagnosis of oral mucosal lesions. 
In our study, we had a positive predictive 
value of 91% which meant that 55 out of the 60 
cases which stained positively for methylene blue 
dye correlated well with the pathologic diagnosis 
of dysplasia. This is much higher than the 
previously reported study which had a positive 
predictive value of 74% (21). 
The negative predictive value in our study 
was 80% which meant that 12 of the 15 cases 




which did not stain with the methylene blue dye 
could also be correlated pathologically which 
showed no evidence of dysplasia. This is in line to 
previous study which reported specificity rate of 
87 % (21). 
In conclusion, this study showed that 
methylene blue staining has nearly 95% sensitivity 
in detecting oral malignant or potentially 
malignant lesions. Considering its low toxicity and 
the fact that it is cheaper than toluidine blue, it 
may be convenient to substitute it for toluidine 
blue in large-scale oral screening of high-risk 
patients. Nevertheless, the pathology report from 
biopsy is still the gold standard to accurately 
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